查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
胃癌治疗市场规模、份额和趋势分析报告：按治疗类型、疾病适应症、给药途径、药物类别、分销渠道、地区、细分市场预测，2022-2030 年
市场调查报告书
商品编码
1122228

胃癌治疗市场规模、份额和趋势分析报告：按治疗类型、疾病适应症、给药途径、药物类别、分销渠道、地区、细分市场预测，2022-2030 年

Stomach Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Disease Indication, By Route Of Administration, By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 140 Pages | 商品交期: 2-10个工作天内

价格

胃癌治疗市场增长和趋势

根据 Grand View Research, Inc. 的一份新报告，到 2030 年，全球胃癌治疗市场规模预计将达到 112 亿美元，从 2022 年到 2030 年，复合年增长率为 12.9%。免疫疗法和靶向疗法的增加以及新药的推出预计将推动增长。

根据Globocan的数据，2020年胃癌的发病率约为110万，预计到2030年将增加到142万。对该疾病分子基础知识的进步导致了靶向和免疫治疗剂的开发和商业化。自 2010 年以来，赫赛汀等 HER-2 靶向药物已上市。此外，一种名为 Cyramza 的靶向药物是一种 VEGF 靶向单克隆抗体，自 2014 年以来已上市。目前，EGFR和PD-1靶向药物和免疫疗法正在开发作为胃癌的治疗药物。

临床管道中药物的批准和随后的上市也有望推动胃癌治疗市场。例如，2021年3月，国家药监局批准Eli Lilly和Innovent Biologics的PD-1抑製剂药物Sintilimab在中国用于治疗胃或胃食管结合部腺癌。此外，2020 年 5 月，美国 FDA 授予 Enhertu 用于胃癌的孤儿药资格。然后，在 2021 年 1 月，美国 FDA 批准 Enhertu 用于治疗晚期或转移性疾病。

赫赛汀等主要药物的专利到期以及随后推出的生物类似药预计将抑制胃癌治疗市场的增长。此外，由于成本高昂而导致靶向治疗的低采用率也可能阻碍市场增长。例如，与其他药物相比，Cyramza 被认为成本效益较低。由于成本效益低，在英国被 NICE 拒绝。此外，与临床相关的比较者相比，法国拒绝报销，因为缺乏额外的好处。

胃癌治疗市场报告亮点

由于强大的临床管道和新产品的批准，靶向治疗治疗类型在 2021 年占销售额的第二大份额。例如，2021年1月，美国FDA批准Enhertu用于治疗转移性或局部晚期HER-2阳性胃癌患者。

按治疗类型，由于 Opdivo 和 Keytruda 等 PD-1 抑製剂在胃癌治疗市场的引入和采用，预计免疫治疗在预测期内增长最快。

根据指示，胃癌/胃食管结合部癌由于其高患病率和产品种类繁多，预计在预测期内将保持领先地位。由于产品推出数量的增加，胃肠道间质瘤（GIST）部分预计将增长

从分销渠道来看，2021年胃癌治疗市场由专业药房和零售药房主导。靶向和免疫治疗药物通常在储存和物流方面有特殊要求，并且通常通过专业药房分发。

由于该地区的高疾病负担和研究计划，预计亚太地区将在预测期内保持其主导地位。根据 Globocan 的报告，到 2020 年，亚洲将占新增胃癌病例的约 75.3%。

由于患者人数增加以及靶向和免疫治疗药物的批准，预计欧洲在预测期内将出现显着增长。

目录

第一章 调查方法和范围

  • 调查方法
  • 调查假设
    • 估计/预测时间表
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
    • 第一次调查的内容
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 型号详情
    • 商品流向分析
      • 方法一：商品流动方法
      • 方法 2：使用自下而上的方法进行国别市场估算
  • 全球市场：复合年增长率计算
  • 二级信息列表
  • 主要信息列表
  • 目的
  • 表列表

第二章执行摘要

  • 市场概况
  • 市场细分

第三章市场变量、趋势和范围

  • 绘製渗透率和增长前景
  • 监管框架
  • 胃癌治疗市场动态
    • 市场驱动力分析
      • 强大的产品管道
      • 疾病流行率增加
    • 市场约束分析
      • 目前批准的靶向治疗缺乏报销
    • 市场机会分析
  • PESTEL 分析
  • 波特五力分析
  • 重大交易和战略联盟分析
    • 新产品发布
    • 扩张
    • 合伙
    • 协议
  • 管道分析
    • 即将推出的主要产品分析
  • 各国流行病学分析
  • 未满足的需求

第 4 章治疗业务分析（患者占比 %）

  • 胃癌治疗市场：治疗类型的变化分析
  • 化学处理
  • 免疫疗法
  • 靶向治疗
  • 放射治疗和手术

第五章 适应症业务分析

  • 胃癌治疗市场：疾病适应症的波动分析
  • 胃癌/食管胃结合部癌
  • 胃肠道间质瘤

6. 医药类业务分析（患者份额%）

  • 胃癌治疗市场：药物类别变化分析
  • PD-1/PD-L1 抑製剂
  • HER2拮抗剂
  • VEGFR2拮抗剂
  • 其他

第七章 管理渠道业务分析

  • 胃癌治疗市场：给药途径的变化分析
  • 口服
  • 可注射的

第八章分销渠道业务分析

  • 胃癌治疗市场：分销渠道波动分析
  • 医院药房
  • 专业和零售药店
  • 其他

第九章区域估计与趋势分析

  • 区域市场快照
    • 北美
      • 美国
      • 加拿大
    • 欧洲
      • 英国
      • 德国
      • 西班牙
      • 法国
      • 意大利
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 韩国
      • 澳大利亚
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
    • 中东和非洲
      • 南非
      • 沙特阿拉伯
      • 阿拉伯联合酋长国

第 10 章胃癌市场 - 竞争分析

  • 主要市场参与者的最新发展和影响分析
  • 公司/竞争对手分类（主要创新者、市场领导者、初创企业）
  • 上市公司
    • 公司市场分析（收入、地域分布、产品组合、关键服务行业、关键联盟）
    • 竞争仪錶盘分析
      • 市场差异化因素
  • 民营企业
    • 主要初创企业/技术颠覆者/创新者名单
    • 区域网络图
    • 公司市场分析（地理分布、产品组合、关键合作伙伴、行业经验）
  • 公司简介
    • Eli Lilly and Company
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • F. Hoffmann-La Roche Ltd.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Pfizer Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Novartis AG
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Merck & Co., Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Samsung Bioepis
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Biocon
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Mylan NV
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Teva Pharmaceutical Industries Ltd.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Celltrion Healthcare Co., Ltd.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
Product Code: GVR-4-68039-973-9

Stomach Cancer Treatment Market Growth & Trends:

The global stomach cancer treatment market size is expected to reach USD 11.2 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 12.9% from 2022 to 2030. Increasing uptake of immunotherapy and targeted therapy, coupled with the launch of new drugs, is expected to fuel growth.

According to Globocan, the incidence of gastric cancer in 2020 was around 1.1 million, which is expected to increase to 1.42 million by 2030. Increasing knowledge regarding the molecular basis of the disease has led to a rise in the number of targeted drugs and immunotherapy drugs being developed and launched in the market. HER-2 targeted drugs such as Herceptin have been available in the market since 2010. Another targeted drug, Cyramza, which is a VEGF-targeting monoclonal antibody, has been available since 2014. EGFR and PD-1 targeted drugs and immunotherapies are currently being developed for the treatment of gastric cancer.

The approval and subsequent launch of drugs in the clinical pipeline are also expected to drive the gastric cancer therapy market. For instance, in March 2021, the NMPA approved Eli Lilly and Innovent Biologics' drug Sintilimab, a PD-1 inhibitor, for the treatment of gastric or gastroesophageal junction adenocarcinoma in China. Furthermore, in May 2020, the U.S. FDA granted the orphan drug designation to Enhertu for the treatment of gastric cancers. Subsequently, in January 2021, the U.S. FDA approved Enhertu for the treatment of advanced or metastatic forms of the disease.

Patent expiry of key drugs such as Herceptin and subsequent launch of biosimilars are expected to restrain the growth of the gastric cancer therapy market. Additionally, lesser adoption of targeted therapy due to high costs might hamper the growth of the market. For instance, Cyramza was not considered cost-effective as compared to other drugs. It was rejected by NICE due to a lack of cost-effectiveness in England. Furthermore, the product was rejected for reimbursement in France due to a lack of additional benefits compared to the clinically relevant comparators.

Stomach Cancer Treatment Market Report Highlights:

  • The targeted therapy treatment type segment held the second-largest revenue share in 2021 due to the robust clinical pipeline and approval of new products. For instance, in January 2021, the U.S. FDA approved Enhertu for the treatment of patients with metastatic or locally advanced HER-2 positive gastric cancers
  • By treatment type, immunotherapy is anticipated to witness the fastest growth during the forecast period due to the launch and adoption of PD-1 inhibitors such as Opdivo and Keytruda in the gastric cancer therapy market
  • By disease indication, the gastric cancer/gastroesophageal junction cancer segment is expected to maintain its lead during the forecast period due to the high prevalence of the disease and the availability of various products. The gastrointestinal stromal tumors (GISTs) segment is expected to grow due to the increasing number of product launches
  • Based on the distribution channel, the specialty and retail pharmacies segment dominated the gastric cancer therapy market in 2021. Targeted and immunotherapy drugs often have special requirements in terms of storage and logistics and are therefore distributed by specialty pharmacies
  • Asia Pacific is expected to maintain its dominance during the forecast period due to the high disease burden and research initiatives in the region. According to a Globocan report, Asia accounts for around 75.3% of all new cases of gastric cancer in 2020
  • Europe is anticipated to witness considerable growth during the forecast period owing to the increasing target patient population and approval of targeted and immunotherapy drugs

TABLE of Contents

Chapter 1 Methodology and Scope

  • 1.1 Research Methodology
  • 1.2 Research Assumptions
    • 1.2.1 Estimates and Forecast Timeline
  • 1.3 Research Methodology
  • 1.4 Information Procurement
    • 1.4.1 Purchased Database
    • 1.4.2 GVR's Internal Database
    • 1.4.3 Secondary Sources
    • 1.4.4 Primary Research
    • 1.4.5 Details of Primary Research
  • 1.5 Information or Data Analysis
    • 1.5.1 Data Analysis Models
  • 1.6 Market Formulation & Validation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis
      • 1.7.1.1 Approach 1: Commodity Flow Approach
      • 1.7.1.2 Approach 2: Country wise market estimation using bottom up approach
  • 1.8 Global Market: CAGR Calculation
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1:
    • 1.11.2 Objective 2:
  • 1.12 List of TABLEs

Chapter 2 Executive Summary

  • 2.1 Market Summary
  • 2.2 Market Segmentation

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Penetration and Growth Prospect Mapping
  • 3.2 Regulatory framework
  • 3.3 Stomach Cancer Treatment Market Dynamics
    • 3.3.1 Market Driver Analysis
      • 3.3.1.1 Robust product pipeline
      • 3.3.1.2 Increasing prevalence of the disease
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 Lack of reimbursement for currently approved targeted therapies
    • 3.3.3 Market Opportunity Analysis
  • 3.4 PESTEL Analysis
  • 3.5 Porter's Five Forces Analysis
  • 3.6 Major deals and strategic alliances analysis
    • 3.6.1 New product launch
    • 3.6.2 Expansion
    • 3.6.3 Partnership
    • 3.6.4 Agreements
  • 3.6 Pipeline Analysis
    • 3.6.1 Analysis of key upcoming products
  • 3.7 Epidemiology Analysis, by Country
  • 3.8 Unmet Needs

Chapter 4 Treatment Type Business Analysis (Patient Share in %)

  • 4.1 Stomach Cancer Treatment Market: Treatment Type Movement Analysis
  • 4.2 Chemotherapy
    • 4.2.1 Chemotherapy market estimates and forecast, 2018 - 2030
  • 4.3 Immunotherapy
    • 4.3.1 Immunotherapy market estimates and forecast, 2018 - 2030
  • 4.4 Targeted Therapy
    • 4.4.1 Targeted Therapy market estimates and forecast, 2018 - 2030
  • 4.4 Radiation therapy & Surgery

Chapter 5 Disease Indication Business Analysis

  • 5.1 Stomach Cancer Treatment Market: Disease Indication Movement Analysis
  • 5.2 Gastric Cancer/Gastroesophageal Junction Cancer
    • 5.2.1 Gastric Cancer/Gastroesophageal Junction Cancer market estimates and forecast, 2018 - 2030
  • 5.3 Gastrointestinal Stromal Tumors
    • 5.3.1 Gastrointestinal Stromal Tumors market estimates and forecast, 2018 - 2030

Chapter 6 Drug Class Business Analysis (Patient Share in %)

  • 6.1 Stomach Cancer Treatment Market: Drug Class Movement Analysis
  • 6.2 PD-1/PD-L1 inhibitors
    • 6.2.1 PD-1/PD-L1 inhibitors market estimates and forecast, 2018 - 2030
  • 6.3 HER2 antagonists
    • 6.3.1 HER2 antagonists market estimates and forecast, 2018 - 2030
  • 6.4 VEGFR2 antagonists
    • 6.4.1 VEGFR2 antagonists market estimates and forecast, 2018 - 2030
  • 6.5 Others
    • 6.5.1 Others market estimates and forecast, 2018 - 2030

Chapter 7 Route of Administration Business Analysis

  • 7.1 Stomach Cancer Treatment Market: Route of Administration Movement Analysis
  • 7.2 Oral
    • 7.2.1 Oral market estimates and forecast, 2018 - 2030
  • 7.3 Injectable
    • 7.3.1 Injectable market estimates and forecast, 2018 - 2030

Chapter 8 Distribution Channel Business Analysis

  • 8.1 Stomach Cancer Treatment Market: Distribution Channel Movement Analysis
  • 8.2 Hospital Pharmacies
    • 8.2.1 Hospital Pharmacies market estimates and forecast, 2018 - 2030
  • 8.3 Specialty & Retail Pharmacies
    • 8.3.1 Specialty & Retail Pharmacies market estimates and forecast, 2018 - 2030
  • 8.4 Others
    • 8.4.1 Others market estimates and forecast, 2018 - 2030

Chapter 9 Regional Estimates & Trend Analysis

  • 9.1. Regional Market Snapshot
    • 9.1.1. North America
      • 9.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.1.2. U.S.
      • 9.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.1.3. Canada
      • 9.1.1.3.1. Canada market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.1.2. Europe
      • 9.1.2.1. Europe market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.2.2. U.K.
      • 9.1.2.2.1. U.K. market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.2.3. Germany
      • 9.1.2.3.1. Germany market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.2.4. Spain
      • 9.1.2.4.1. Spain market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.2.5. France
      • 9.1.2.5.1. France market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.2.9. Italy
      • 9.1.2.9.1. Italy market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.1.3. Asia Pacific
      • 9.1.3.1.Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.3.2. China
      • 9.1.3.2.1. China market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.3.3. Japan
      • 9.1.3.3.1. Japan market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.3.4. India
      • 9.1.3.4.1. India market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.3.5. South Korea
      • 9.1.3.5.1. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.3.9. Australia
      • 9.1.3.9.1. Australia market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.1.4. Latin America
    • 9.1.4. Latin America market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.4.1. Brazil
      • 9.1.4.1.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.4.2. Mexico
      • 9.1.4.2.1. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.4.3. Argentina
      • 9.1.4.3.1. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.1.5. Middle East & Africa
      • 9.1.5.1. MEA market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.5.2. South Africa
      • 9.1.5.2.1. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.5.3. Saudi Arabia
      • 9.1.5.3.1. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.5.4. UAE
      • 9.1.5.4.1. UAE market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 10 Stomach Cancer Market - Competitive Analysis

  • 10.1. Recent developments & impact analysis, by key market participants
  • 10.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
  • 10.3. Public Companies
    • 10.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
    • 10.3.2. Competitive Dashboard Analysis
      • 10.3.2.1. Market Differentiators
  • 10.4. Private Companies
    • 10.4.1. List of key emerging companies' /technology disruptors/innovators
    • 10.4.2. Regional network map
    • 10.4.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
  • 10.5. Company Profiles
    • 10.5.1. Eli Lilly and Company
      • 10.5.1.1. Company Overview
      • 10.5.1.2. Financial Performance
      • 10.5.1.3. Product Benchmarking
      • 10.5.1.4. Strategic Initiatives
    • 10.5.2. F. Hoffmann-La Roche Ltd.
      • 10.5.2.1. Company Overview
      • 10.5.2.2. Financial Performance
      • 10.5.2.3. Product Benchmarking
      • 10.5.2.4. Strategic Initiatives
    • 10.5.3. Pfizer Inc.
      • 10.5.3.1. Company Overview
      • 10.5.3.2. Financial Performance
      • 10.5.3.3. Product Benchmarking
      • 10.5.3.4. Strategic Initiatives
    • 10.5.4. Novartis AG
      • 10.5.4.1. Company Overview
      • 10.5.4.2. Financial Performance
      • 10.5.4.3. Product Benchmarking
      • 10.5.4.4. Strategic Initiatives
    • 10.5.5. Merck & Co., Inc.
      • 10.5.5.1. Company Overview
      • 10.5.5.2. Financial Performance
      • 10.5.5.3. Product Benchmarking
      • 10.5.5.4. Strategic Initiatives
    • 10.5.6. Samsung Bioepis
      • 10.5.6.1. Company Overview
      • 10.5.6.2. Financial Performance
      • 10.5.6.3. Product Benchmarking
      • 10.5.6.4. Strategic Initiatives
    • 10.5.10. Biocon
      • 10.5.10.1. Company Overview
      • 10.5.10.2. Financial Performance
      • 10.5.10.3. Product Benchmarking
      • 10.5.10.4. Strategic Initiatives
    • 10.5.8. Mylan N.V.
      • 10.5.8.1. Company Overview
      • 10.5.8.2. Financial Performance
      • 10.5.8.3. Product Benchmarking
      • 10.5.8.4. Strategic Initiatives
    • 10.5.9. Teva Pharmaceutical Industries Ltd.
      • 10.5.9.1. Company Overview
      • 10.5.9.2. Financial Performance
      • 10.5.9.3. Product Benchmarking
      • 10.5.9.4. Strategic Initiatives
    • 10.5.10. Celltrion Healthcare Co., Ltd.
      • 10.5.10.1. Company Overview
      • 10.5.10.2. Financial Performance
      • 10.5.10.3. Product Benchmarking
      • 10.5.10.4. Strategic Initiatives

List of Tables

  • TABLE 1 List of Secondary Sources
  • TABLE 2 List of Abbreviations
  • TABLE 3 Global Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (Patient Share in %, USD Million)
  • TABLE 4 Global Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (Patient Share in %, USD Million)
  • TABLE 5 Global Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 6 Global Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 7 Global Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 8 Global Stomach Cancer Treatment market, by Region, 2018 - 2030 (USD Million)
  • TABLE 9 North America Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
  • TABLE 10 North America Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 11 North America Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 12 North America Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 13 North America Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 14 North America Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 15 U.S. Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 16 U.S. Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 17 U.S. Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 18 U.S. Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 19 U.S. Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 20 Canada Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 21 Canada Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 22 Canada Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 23 Canada Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 24 Canada Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 25 Europe Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
  • TABLE 26 Europe Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 27 Europe Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 28 Europe Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 29 Europe Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 30 Europe Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 31 Germany Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 32 Germany Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 33 Germany Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 34 Germany Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 35 Germany Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 36 U.K. Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 37 U.K. Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 38 U.K. Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 39 U.K. Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 40 U.K. Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 41 France Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 42 France Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 43 France Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 44 France Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 45 France Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 46 Italy Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 47 Italy Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 48 Italy Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 49 Italy Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 50 Italy Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 51 Spain Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 52 Spain Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 53 Spain Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 54 Spain Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 55 Spain Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 56 Asia Pacific Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
  • TABLE 57 Asia Pacific Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 58 Asia Pacific Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 59 Asia Pacific Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 60 Asia Pacific Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 61 Asia Pacific Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 62 China Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 63 China Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 64 China Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 65 China Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 66 China Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 67 Japan Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 68 Japan Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 69 Japan Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 70 Japan Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 71 Japan Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 72 India Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 73 India Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 74 India Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 75 India Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 76 India Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 77 South Korea Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 78 South Korea Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 79 South Korea Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 80 South Korea Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 81 South Korea Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 82 Australia Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 83 Australia Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 84 Australia Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 85 Australia Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 86 Australia Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 87 Latin America Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
  • TABLE 88 Latin America Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 89 Latin America Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 90 Latin America Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 91 Latin America Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 92 Latin America Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 93 Brazil Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 94 Brazil Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 95 Brazil Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 96 Brazil Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 97 Brazil Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 98 Mexico Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 99 Mexico Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 100 Mexico Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 101 Mexico Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 102 Mexico Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 103 Argentina Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 104 Argentina Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 105 Argentina Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 106 Argentina Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 107 Argentina Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 108 Middle East & Africa Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
  • TABLE 109 Middle East & Africa Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 110 Middle East & Africa Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 111 Middle East & Africa Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 112 Middle East & Africa Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 113 Middle East & Africa Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 114 South Africa Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 115 South Africa Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 116 South Africa Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 117 South Africa Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 118 South Africa Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 119 Saudi Arabia Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 120 Saudi Arabia Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 121 Saudi Arabia Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 122 Saudi Arabia Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 123 Saudi Arabia Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 124 UAE Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 125 UAE Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 126 UAE Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 127 UAE Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 128 UAE Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary Research Pattern
  • FIG. 4 Market Research Approaches
  • FIG. 5 Epidemiology - based market sizing & Forecasting
  • FIG. 6 Market Formulation & Validation
  • FIG. 7 Stomach Cancer Treatment Market, Market Segmentation
  • FIG. 8 Market Snapshot, 2021
  • FIG. 9 Market Trends & Outlook
  • FIG. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • FIG. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • FIG. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • FIG. 13 Porter's Five Forces Analysis
  • FIG. 14 Market Penetration Vs Growth Prospect Mapping, 2021
  • FIG. 15 Global Stomach Cancer Treatment Market:Treatment Type Movement Analysis
  • FIG. 16 Global Stomach Cancer Treatment Market, for Chemotherapy, 2018 - 2030 (Patient Share in %, USD Million)
  • FIG. 17 Global Stomach Cancer Treatment Market, for Immunotherapy, 2018 - 2030 (Patient Share in %, USD Million)
  • FIG. 18 Global Stomach Cancer Treatment Market, for Targeted drugs, 2018 - 2030 (Patient Share in %, USD Million)
  • FIG. 19 Global Stomach Cancer Treatment Market: Disease Indication Movement Analysis
  • FIG. 20 Global Stomach Cancer Treatment Market, for Gastric Cancer/Gastroesophageal Junction Cancer, 2018 - 2030 (USD Million)
  • FIG. 21 Global Stomach Cancer Treatment Market, for Gastrointestinal Stromal Tumors, 2018 - 2030 (USD Million)
  • FIG. 22 Global Stomach Cancer Treatment Market: Route of Administration Movement Analysis
  • FIG. 23 Global Stomach Cancer Treatment Market, for Oral, 2018 - 2030 (USD Million)
  • FIG. 24 Global Stomach Cancer Treatment Market, for Injectable, 2018 - 2030 (USD Million)
  • FIG. 25 Global Stomach Cancer Treatment Market: Drug Class, Movement Analysis
  • FIG. 26 Global Stomach Cancer Treatment Market, for PD - 1/ PD - L1 inibitors, 2018 - 2030 (Patient Share in %, USD Million)
  • FIG. 27 Global Stomach Cancer Treatment Market, for HER2 Antagonists, 2018 - 2030 (Patient Share in %, USD Million)
  • FIG. 28 Global Stomach Cancer Treatment Market, for VEGFR Antagonists, 2018 - 2030 (Patient Share in %, USD Million)
  • FIG. 29 Global Stomach Cancer Treatment Market, for Others, 2018 - 2030 (Patient Share in %, USD Million)
  • FIG. 30 Global Stomach Cancer Treatment Market: Distribution Channel, Movement Analysis
  • FIG. 31 Global Stomach Cancer Treatment Market, for Hospital Pharmacies, 2018 - 2030 (USD Million)
  • FIG. 32 Global Stomach Cancer Treatment Market, for Specialty & Retail Pharmacies, 2018 - 2030 (USD Million)
  • FIG. 33 Global Stomach Cancer Treatment Market, for Others, 2018 - 2030 (USD Million)
  • FIG. 34 Regional Marketplace: Key Takeaways
  • FIG. 35 Regional Outlook, 2021 & 2030
  • FIG. 36 Global Stomach Cancer Treatment Market: Regional Movement Analysis
  • FIG. 37 North AmericaStomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 38 U.S. Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 39 Canada Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 40 Europe Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 41 Germany Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 42 U.K. Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 43 France Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 44 Italy Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 45 Spain Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 46 Asia Pacific Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 47 Japan Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 48 China Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 49 India Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 50 Australia Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 51 South Korea Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 52 Latin AmericaStomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 53 Brazil Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 54 Mexico Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 55 Argentina Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 56 Middle East and Africa Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 57 South Africa Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 58 Saudi Arabia Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 59 UAE Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)